CTRI/2023/07/055678招募中3 期
Clinical study to evaluate the efficacy of Tonsenorm compound in the management of Tundikeri with special reference to chronic Tonsillitis in children - NI
试验速览
- 阶段
- 3 期
- 状态
- 招募中
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •1. Children of either sex in between age group of 05 to 10 years.
- •2.Patients presenting with symptoms of Tundikeri and/or Chronic tonsillitis.
- •3. Patients clinically having chronic tonsillitis from grade 1 to 3
排除标准
- •1.Patients clinically having chronic tonsillitis of grade 4.
- •2. Patients presenting with Acute pharyngotonsillitis.
- •3. Patient with complications of Tonsillitis like peritonsillar abscess,
- •retropharyngeal abscess, parapharyngeal abscess etc.
- •4. Patients on other drugs which may change the outcome of trial drug.
- •5. Immunocompromised patients e.g., patients suffering from HIV, Tuberculosis
研究者
相似试验
已完成
不适用
A clinical study for evaluating the efficacy of test food on the suppression of the elevation of postprandial blood glucose level. -Randomised double-blind placebo-controlled trialHealthy adultJPRN-UMIN000035336KSO Corporation50
已完成
不适用
A clinical study for evaluating the efficacy of test food on the suppression of the elevation of postprandial blood glucose levelHealthy adultJPRN-UMIN000043321Pharma Foods International Co., Ltd.30
已完成
不适用
A clinical study for evaluating the efficacy of test food on the suppression of the elevation of postprandial serum triglyceride. : Randomised double-blind placebo-controlled trialHealthy adultJPRN-UMIN000036241Allegro Inc.30
已完成
不适用
A clinical study for evaluating the efficacy of test food on the suppression of the elevation of postprandial serum triglyceride. -Randomised double-blind placebo-controlled trialHealthy adultJPRN-UMIN000035337KSO Corporation80
已完成
不适用
A clinical study for evaluating the efficacy of test food on the suppression of the elevation of postprandial blood glucose level : Randomised double-blind placebo-controlled trialHealthy adultJPRN-UMIN000036242Allegro Inc.30